PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799107
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799107
Asthma Drugs
Global Asthma Drugs Market to Reach US$33.1 Billion by 2030
The global market for Asthma Drugs estimated at US$25.1 Billion in the year 2024, is expected to reach US$33.1 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Bronchodilators, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$21.0 Billion by the end of the analysis period. Growth in the Anti-inflammatory Drugs segment is estimated at 3.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 8.7% CAGR
The Asthma Drugs market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.0 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.
Global Asthma Drugs Market - Key Trends & Drivers Summarized
How Is Innovation Shaping the Modern Landscape of Asthma Drug Development?
Asthma, a chronic respiratory condition affecting over 300 million people globally, continues to evolve as a key focal point for pharmaceutical innovation. The asthma drugs market has been undergoing a remarkable transformation driven by rapid advancements in drug formulations and targeted therapies. Over the past decade, pharmaceutical companies have moved away from traditional corticosteroid-based therapies and bronchodilators toward more sophisticated biologics and monoclonal antibodies. These targeted treatments such as omalizumab, mepolizumab, benralizumab, and dupilumab are designed to address the underlying inflammatory pathways of asthma rather than merely alleviating symptoms. The integration of precision medicine and pharmacogenomics has further enhanced drug efficacy by tailoring treatments to individual genetic profiles. Moreover, there has been significant investment in inhalation technology, resulting in next-generation smart inhalers that not only deliver drugs more effectively but also track patient adherence and usage patterns via digital connectivity. The development pipeline remains robust with numerous clinical trials targeting both eosinophilic and non-eosinophilic asthma phenotypes, offering renewed hope for patients previously unresponsive to standard therapies. With regulatory bodies like the FDA and EMA fast-tracking approvals for novel biologics and granting orphan drug designations, the industry is poised for sustained innovation that continually redefines the standard of asthma care.
Why Are Shifting Demographics and Lifestyle Patterns Creating New Market Opportunities?
The changing demographics of the global population, alongside urbanization and environmental shifts, are significantly impacting the asthma drugs market. Urban populations, particularly in rapidly developing nations such as India, China, and parts of Southeast Asia, are experiencing increased exposure to pollution, allergens, and occupational irritants, all of which elevate asthma prevalence rates. Compounding this trend is the rise in obesity, sedentary lifestyles, and unhealthy dietary habits, all of which are recognized contributors to asthma exacerbation. Additionally, aging populations in Western economies are presenting unique challenges and opportunities, as elderly asthma patients often have comorbidities that necessitate tailored therapeutic strategies and drug safety profiles. Pediatric asthma, too, remains a major concern, prompting pharmaceutical firms to develop child-friendly formulations, including flavored inhalers, dissolvable tablets, and nebulized solutions with minimal side effects. Consumer awareness, bolstered by public health campaigns and online education, has also led to increased diagnosis rates and proactive disease management. In many markets, the stigma around asthma is diminishing, resulting in more people seeking early treatment and maintenance therapy, which, in turn, drives demand for preventive medications and long-term care options. Together, these factors are shifting the target consumer base and compelling drug developers to diversify product offerings suited to different age groups, comorbidity profiles, and regional health challenges.
Could Market Access and Healthcare Infrastructure Be the Decisive Factors in Regional Growth?
Accessibility, affordability, and the robustness of healthcare systems continue to define the regional dynamics of the asthma drugs market. Developed markets such as North America and Europe are characterized by advanced healthcare infrastructure, comprehensive insurance coverage, and high levels of physician awareness, all of which contribute to early diagnosis and sustained drug adherence. In these regions, pricing strategies for premium biologics and combination therapies are supported by reimbursement frameworks and public healthcare systems. On the other hand, low- and middle-income countries are grappling with underdiagnosis, inadequate access to specialist care, and out-of-pocket healthcare expenditures that limit market penetration for high-cost treatments. However, initiatives from global organizations such as WHO and GINA, in partnership with local governments, are improving access to essential asthma medications by endorsing affordable generics and standard treatment protocols. Telemedicine and mobile health platforms are playing an increasingly critical role in rural and underserved areas, enabling remote consultations and medication monitoring, especially in geographies where pulmonologists are scarce. Multinational pharma companies are also engaging in strategic partnerships with local manufacturers to reduce distribution costs and comply with regional regulatory requirements. As more countries prioritize chronic respiratory conditions within their public health agendas, the stage is set for significant growth in emerging markets, contingent on investments in healthcare access and patient education.
What Are the Underlying Forces Driving Market Expansion at This Decisive Moment?
The growth in the asthma drugs market is driven by several factors related to technology innovation, therapeutic demand patterns, consumer behavior, and healthcare system evolution. First, the technological progress in biologics and targeted immunotherapies has created a new class of highly effective treatments that address both moderate and severe forms of asthma, appealing to a broader spectrum of patients. The proliferation of smart inhalers and digital therapeutics is reshaping drug delivery, enabling more precise dosing and real-time monitoring, which improves compliance and treatment outcomes. Secondly, the rising incidence of asthma, particularly in urban and industrializing regions, is increasing the patient population requiring both acute and maintenance therapies. Consumer behavior is also shifting, with patients becoming more health-conscious, digitally informed, and inclined toward preventive care rather than reactive treatment. This has elevated demand for maintenance drugs and personalized treatment regimens. Meanwhile, healthcare providers are adapting by integrating asthma care into primary health services, increasing routine screening, and leveraging data analytics to identify high-risk individuals. In terms of end-use environments, hospitals, specialty clinics, and even home care settings are expanding their use of asthma drugs due to advancements in portable drug delivery systems and remote monitoring solutions. Finally, favorable policy support, global initiatives to reduce air pollution, and public-private partnerships aimed at improving drug access and affordability are creating a conducive environment for sustained market growth across both developed and emerging regions.
SCOPE OF STUDY:
The report analyzes the Asthma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies Combination Drugs)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 36 Featured) -
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Boehringer Ingelheim
- Chiesi Farmaceutici S.p.A
- Cipla Ltd.
- Covis Pharma
- Gedeon Richter Plc
- Glenmark Pharmaceuticals
- GSK plc (GlaxoSmithKline)
- Kyorin Pharmaceutical Co.
- Lupin Limited
- Merck & Co., Inc.
- Novartis AG
- Orion Corporation
- Sanofi S.A.
- Sun Pharmaceutical
- Teva Pharmaceutical
- Theravance Biopharma
- Vectura Group
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Asthma Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Biologics Boom Throws the Spotlight on Monoclonal Antibodies as the Future of Severe Asthma Treatment
- Digital Health Integration Spurs Growth in Personalized Asthma Therapy Management
- Rising Global Pollution Levels Expand the Addressable Market Opportunity for Asthma Medications
- Inhaler Technology Advancements Strengthen the Business Case for Device-Drug Combinations
- Aging Population and Comorbidities Generate Sustained Demand for Long-Term Asthma Control Solutions
- Real-World Evidence (RWE) Strategies Propel Growth in Label Expansion and Reimbursement Approvals
- Growing Emphasis on Environmental Sustainability Creates Challenges for Propellant-Based Inhalers
- Telemedicine Penetration Accelerates Demand for Remote Prescription and Symptom Monitoring Solutions
- Rising Asthma Prevalence in Emerging Economies Expands Market Penetration Opportunities
- Precision Medicine Approaches Drive Interest in Biomarker-Based Asthma Drug Development
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Asthma Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Asthma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Monoclonal Antibodies Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Monoclonal Antibodies Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: USA 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- JAPAN
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- CHINA
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: China Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: China 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- EUROPE
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Asthma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- FRANCE
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: France Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: France 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- GERMANY
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: UK 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 44: Spain Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Spain Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Spain 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 47: Russia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Russia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Russia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Rest of Europe Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Rest of Europe 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Asia-Pacific Historic Review for Asthma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Asia-Pacific 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Asia-Pacific 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- AUSTRALIA
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 59: Australia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Australia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: Australia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- INDIA
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 62: India Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: India Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: India 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 65: South Korea Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: South Korea Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: South Korea 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Rest of Asia-Pacific Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 71: Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 72: Latin America Historic Review for Asthma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: Latin America 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 74: Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Latin America Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Latin America 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 77: Argentina Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Argentina Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Argentina 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 80: Brazil Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Brazil Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: Brazil 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 83: Mexico Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Mexico Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Mexico 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Latin America Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Rest of Latin America 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 89: Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 90: Middle East Historic Review for Asthma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Middle East 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 92: Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Middle East Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Middle East 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- IRAN
- TABLE 95: Iran Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Iran Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Iran 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 98: Israel Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Israel Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Israel 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Saudi Arabia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: Saudi Arabia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 104: UAE Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: UAE Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: UAE 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Rest of Middle East Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: Rest of Middle East 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
- AFRICA
- Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 110: Africa Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Africa Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 112: Africa 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
IV. COMPETITION
